If what France is reporting is true as in Medscape UK as to an unusual rise in mycoplasma pneumoniae Respiratory Infections that mirrors China in kids, then we are likely witnessing SYSTEMIC COVID

mRNA technology vaccine-induced immune subversion, suppression (Dr. Hodkinson concurs) likely with immune damage due to lockdowns; evidence of DOXYCYCLINE working to treat

"The vast majority of Mycoplasma pneumoniae infections are benign and heal spontaneously." This is echoed by the WHO, which said "Mycoplasma pneumoniae is a common respiratory pathogen and a frequent cause of paediatric pneumonia, easily treatable with antibiotics."

https://www.medscape.co.uk/viewarticle/unusual-rise-mycoplasma-pneumoniae-respiratory-infections-2023a1000tue?ecd=wnl_tp10_daily_231204_MSCPEDIT_etid6122136&uac=401559MJ&impID=6122136&sso=true

‘The first-line empirical antibiotic treatment for Mycoplasma pneumoniae pneumopathy relies on macrolides, administered as monotherapy.’

https://www.medscape.co.uk/viewarticle/unusual-rise-mycoplasma-pneumoniae-respiratory-infections-2023a1000tue?ecd=wnl_tp10_daily_231204_MSCPEDIT_etid6122136&uac=401559MJ&impID=6122136&sso=true

“The Directorate General of Health said, "In the presence of bacterial pneumopathy, and in the absence of immediately indicative signs of an atypical bacterium (gradual onset, extra-respiratory signs, preserved general condition, nonsystematised opacity), the first-line treatment remains amoxicillin or amoxicillin/clavulanic acid as per usual recommendations. In this case, clinical reassessment after 48-72 hours of initial antibiotic therapy is imperative. If unsuccessful, a change to macrolides is suggested after a control chest X-ray to rule out pleural effusion and/or a CRP [test]."

Furthermore, "Chest X-ray can guide diagnosis in the presence of diffuse bilateral interstitial lung infiltrate. Radiological anomalies are inconsistent, and low-dose thoracic CT scans perform better in this regard. Reminder: complementary investigations depend on pneumonia severity and should not delay empirical treatment."

https://www.medscape.co.uk/viewarticle/unusual-rise-mycoplasma-pneumoniae-respiratory-infections-2023a1000tue?ecd=wnl_tp10_daily_231204_MSCPEDIT_etid6122136&uac=401559MJ&impID=6122136&sso=true

There appears to be a co-circulation of mycobacterium mycoplasma pneumoniae with three other respiratory viruses influenza/RSV/COVID, and symptoims may mirror each other. IMO we can tie all 4 infections to the mRNA technology gene based COVID injections.